Montelukast Zentiva

Montelukast, the active ingredient in Montelukast Zentiva, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children who require long‑term control of airway inflammation.

GNH USA supplies Montelukast Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to manage chronic airway and allergic conditions.

- Asthma: improves long‑term control and reduces exacerbations in patients with persistent asthma. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported. - Abdominal pain: discomfort or cramping in the stomach area. - Cough: occasional dry or productive cough. - Nausea: feeling of queasiness or urge to vomit. - Diarrhea: loose, watery stools. - Fatigue: unusual tiredness or lack of energy.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Mood changes: depression, anxiety, or suicidal thoughts. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Liver injury: elevated enzymes or hepatitis. - Angioedema: rapid swelling of face, lips, or throat. - Blood dyscrasias: rare cases of neutropenia or eosinophilia.

Before initiating therapy, consider the following safety measures.

- Assess liver function: monitor patients with hepatic impairment. - Review psychiatric history: observe for mood changes or suicidal ideation. - Evaluate for hypersensitivity: avoid use in individuals with known allergy to montelukast. - Consider age‑related dosing: pediatric patients require careful dose selection by the prescriber. - Avoid use during acute asthma attacks: not a rescue medication. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring attention to potential changes in efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase montelukast plasma concentrations. - Phenobarbital, phenytoin, carbamazepine: can markedly reduce montelukast levels, compromising effectiveness.

Moderate Interactions (Monitor Closely): - Ritonavir: may elevate montelukast exposure, warranting clinical observation. - Rifampin: may lower montelukast concentrations, consider alternative therapy. - Warfarin: occasional reports of altered INR; monitor coagulation parameters. - Beta‑agonists: additive bronchodilation effect, monitor for excessive airway relaxation. - Antidepressants (SSRIs): rare reports of enhanced neuropsychiatric effects; observe mood changes.